Appili Therapeutics (APLIF) Stock Price, Quote, News & History

Appili Therapeutics Inc (APLIF) Stock Price, Quote, News & History

APLIFOTCPK

Trade with Public

$0.0125

-0.0003-2.34%

Last update: Mar 16, 9:32 AM

Key Statistics

Open

$0.01

Volume / Avg.

100.00K / 28.94K

Day Range

$0.01 - $0.01

52 Wk Range

0.01 - 0.03

Market Cap

$1.60M

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

2.53

Recent Appili Therapeutics Inc News

APLIF: Advancing Multiple Programs to Combat Infectious Diseases…

By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT

Zacks Small Cap Research

APLIF: New Late Stage Program to Treat Cutaneous Leishmaniasis…

Bautz: By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT

Zacks Small Cap Research

APLIF: U.S. DoD to Provide Over US$10 Million in Funding for ATI-1701…

By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT

Zacks Small Cap Research

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-11.33K

Investing Cash Flow (TTM)

Financing Cash Flow (TTM)

-31.41K

Free Cash Flow (TTM)

-11.33K

Capital Expenditure (TTM)

Net Change in Cash (TTM)

-42.74K

Valuation Metrics

Enterprise Value

$10.89M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

10.68

PB Ratio (TTM)

Earnings Yield % (TTM)

-114.86%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

-$0.09

Company Debt

Total Debt

$12.46M

LT Debt

$736.80K

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$104.81K

Total Cash

$212.75K

Debt to Equity

Issuance of Debt (TTM)

-$104.81K

Repayment of Debt (TTM)

-$104.81K

Key Statistics

Open

$0.01

Volume / Avg.

100.00K / 28.94K

Day Range

$0.01 - $0.01

52 Wk Range

0.01 - 0.03

Market Cap

$1.60M

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

2.53

About

Sector

Health Care

Industry

Pharmaceuticals

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-17...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Appili Therapeutics (APLIF) stock?

You can purchase shares of Appili Therapeutics (OTCPK:APLIF) through any online brokerage.

View our list of the best stock brokerages

Who are Appili Therapeutics (APLIF) competitors?

There are no as such competitors for Appili Therapeutics.

What is the forecast, or price target, for Appili Therapeutics (APLIF) stock?

There is no analysis for Appili Therapeutics to provide a consensus price target.

What is the current price for Appili Therapeutics (APLIF)?

The stock price for Appili Therapeutics (OTCPK: APLIF) is $0.0125 last updated March 16, 2026 at 9:32 AM EDT.

Does Appili Therapeutics (APLIF) pay a dividend?

There are no upcoming dividends for Appili Therapeutics.

When is Appili Therapeutics (OTCPK:APLIF) reporting earnings?

Appili Therapeutics does not have any upcoming earnings scheduled.

Is Appili Therapeutics (APLIF) going to split?

There is no upcoming split for Appili Therapeutics.

What sector and industry does Appili Therapeutics (APLIF) operate in?

Appili Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the OTCPK.

Key Statistics

Open

$0.01

Volume / Avg.

100.00K / 28.94K

Day Range

$0.01 - $0.01

52 Wk Range

0.01 - 0.03

Market Cap

$1.60M

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

2.53

Recent Appili Therapeutics Inc News

APLIF: Advancing Multiple Programs to Combat Infectious Diseases…

By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT

Zacks Small Cap Research

APLIF: New Late Stage Program to Treat Cutaneous Leishmaniasis…

Bautz: By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT

Zacks Small Cap Research

APLIF: U.S. DoD to Provide Over US$10 Million in Funding for ATI-1701…

By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT

Zacks Small Cap Research